Effect of PARP Inhibitor Combined with Bevacizumab on Platinum-Resistant Recurrent Ovarian Epithelial Carcinoma

CONCLUSION: PARP inhibitor combined with bevacizumab had good effect in the treatment of platinum-resistant recurrent ovarian epithelial carcinoma and can effectively improve the survival time and quality of life of patients.PMID:35720032 | PMC:PMC9205723 | DOI:10.1155/2022/4600145

Source: Computational and Mathematical Methods in Medicine - June 20, 2022 Category: Statistics Authors: Li Sun Caixia Liu Yun Li Source Type: research